Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma
Clinical Lymphoma Myeloma and Leukemia · 2023-05 · 23 (5) · 385-393
DOI: 10.1016/j.clml.2023.02.006 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023-05. Verfasst von María-Victoria Mateos und 16 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital of Salamanca/IBSAL/CIC, Salamanca, Spain. Electronic address: mvmateos@usal.es. Hauptthemen laut MEDLINE: Antineoplastic Agents, Multiple Myeloma, Physicians. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Hospital of Salamanca/IBSAL/CIC, Salamanca, Spain. Electronic address: mvmateos@usal.es.
- Mount Sinai School of Medicine, New York, NY.
- Memorial Sloan Kettering Cancer Center, New York, NY.
- University Hospital Heidelberg, Heidelberg, Germany.
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Janssen Research & Development, Titusville, NJ.
Zitieren
APA
Mateos, M. V., Chari, A., Usmani, S. Z., Goldschmidt, H., Weisel, K., Qi, K., Londhe, A., Nair, S., Lin, X., Pei, L., Ammann, E., Kobos, R., Smit, J., Parekh, T., Marshall, A., Slavcev, M., & Moreau, P. (2023). Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 23(5), 385-393. https://doi.org/10.1016/j.clml.2023.02.006
Vancouver
Mateos MV, Chari A, Usmani SZ, Goldschmidt H, Weisel K, Qi K, et al. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2023;23(5):385-393. doi:10.1016/j.clml.2023.02.006
BibTeX
@article{Mateos2023,
author = {Mateos, María-Victoria and Chari, Ajai and Usmani, Saad Z and Goldschmidt, Hartmut and Weisel, Katja and Qi, Keqin and Londhe, Anil and Nair, Sandhya and Lin, Xiwu and Pei, Lixia and Ammann, Eric and Kobos, Rachel and Smit, Jennifer and Parekh, Trilok and Marshall, Alexander and Slavcev, Mary and Moreau, Philippe},
title = {Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2023},
volume = {23},
number = {5},
pages = {385--393},
doi = {10.1016/j.clml.2023.02.006}
}
EUVIMED